Thrombosis and thrombocytopenia are common in malignancy due to
microangiopathic disorders (thrombocytopenic purpura, immune disorder, immune
thrombocytopenic purpura, and heparin-induced thrombocytopenia), chemotherapy
side effect, or direct cancer effect. Recurrent VTE (while on anticoagulation) is also
common, risk factors include metastasis, young age, and short interval between cancer
diagnosis and VTE. VTE remains a major challenge among those with renal
impairment. Incidental VTE is an unexpected thrombosis detected in a patient
undergoing imaging study for other indications. Incidental VTE has been attributed to
malignancy or chemotherapy side effects. Philadelphia chromosome-negative
Myeloproliferative Disorders (Polycythemia Vera (PV), Essential thrombocytosis (ET),
and Primary Myelofibrosis (PMF) has been implicated with high risk for both venous
and arterial thromboembolism. Venous thromboembolism (VTE) has been increasingly
associated with hematological malignancy as well.
Keywords: Bone marrow transplant and VTE, Cancer-associated thrombosis,
Chemotherapy, Incidental VTE in cancer, Recurrent VTE, Thrombocytopenia,
Thrombosis, Thrombosis in malignancy, VTE and thrombocytopenia, VTE in
myeloproliferative disorder, VTE in renal impairment.
